These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34529289)

  • 41. Conversion From Immediate-Release to Prolonged-Release Tacrolimus in Kidney Transplant Patients With Tremor: A Case Series Study.
    Kamińska D; Hożejowski R; Chamienia A; Dębska-Ślizień A; Idasiak-Piechocka I; Oko A; Baranowicz-Gąszczyk I; Załuska W; Mazanowska O; Krajewska M
    Transplant Proc; 2024 May; 56(4):776-780. PubMed ID: 38453593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-World Administration of Once-Daily MeltDose
    Willuweit K; Frey A; Hörster A; Saner F; Herzer K
    J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33396492
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dosing strategies for
    Diamond A; Karhadkar S; Chavin K; Constantinescu S; Lau KN; Perez-Leal O; Mohrien K; Sifontis N; Di Carlo A
    World J Transplant; 2023 Dec; 13(6):368-378. PubMed ID: 38174147
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature.
    Tran D; Vallée M; Collette S; Senécal L; Lafrance JP; Dandavino R; Boucher A
    Exp Clin Transplant; 2014 Aug; 12(4):323-7. PubMed ID: 24844288
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience.
    Turunc V; Ari E; Guven B; Tabendeh B; Yildiz A
    Transplant Proc; 2019 Sep; 51(7):2308-2311. PubMed ID: 31400977
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians.
    Wiseman A; Alhamad T; Alloway RR; Concepcion BP; Cooper M; Formica R; Klein CL; Kumar V; Leca N; Shihab F; Taber DJ; Mulnick S; Bushnell DM; Hadi M; Bunnapradist S
    Ann Transplant; 2024 Mar; 29():e943498. PubMed ID: 38526543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.
    Garnock-Jones KP
    Drugs; 2015 Feb; 75(3):309-20. PubMed ID: 25613762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dosing Requirements of Extended-Release Tacrolimus (Astagraf XL) in African American Kidney Transplant Recipients Converted from Immediate-Release Tacrolimus (AAAKTRS).
    Fleming JN; Posadas Salas MA; Taber DJ
    Ther Drug Monit; 2020 Jun; 42(3):415-420. PubMed ID: 31913864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative pharmacokinetics of tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus to prolonged-release tacrolimus formulation.
    Rubik J; Debray D; Iserin F; Vondrak K; Sellier-Leclerc AL; Kelly D; Czubkowski P; Webb NJA; Riva S; D'Antiga L; Marks SD; Rivet C; Tönshoff B; Kazeem G; Undre N
    Pediatr Transplant; 2019 Jun; 23(4):e13391. PubMed ID: 30932313
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives.
    Oberbauer R; Bestard O; Furian L; Maggiore U; Pascual J; Rostaing L; Budde K
    Transplant Rev (Orlando); 2020 Apr; 34(2):100531. PubMed ID: 31955920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes in kidney transplant recipients treated with immediate-release tacrolimus capsules versus extended-release tacrolimus capsules: A cohort study.
    Ha YP; Divard G; Mitra N; Putt ME; Pallet N; Loupy A; Anglicheau D; Trofe-Clark J; Legendre C; Bloom RD; Reese PP
    Clin Transplant; 2023 Jan; 37(1):e14840. PubMed ID: 36374204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients.
    Cross SA; Perry CM
    Drugs; 2007; 67(13):1931-43. PubMed ID: 17722962
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
    Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis.
    Saengram W; Vadcharavivad S; Poolsup N; Chancharoenthana W
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1249-1260. PubMed ID: 29961086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness and safety of the conversion to MeltDose
    Sánchez Fructuoso A; Ruiz JC; Franco A; Diekmann F; Redondo D; Calviño J; Serra N; Aladrén MJ; Cigarrán S; Manonelles A; Ramos A; Gómez G; González Posada JM; Andrés A; Beneyto I; Muñiz AL; Perelló M; Lauzurica R
    Clin Transplant; 2020 Jan; 34(1):e13767. PubMed ID: 31815310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adherence to, and patient convenience of, prolonged-release tacrolimus in stable kidney and liver transplant recipients after conversion from immediate-release tacrolimus in routine clinical practice in Switzerland.
    Bonani M; Balaphas A; Bedino G; Bühler L; Dutkowski P; Fausch K; Gluderer S; Graf N; Hirt-Minkowski P; Müllhaupt B; Schönholzer C; Schulz MM; Venzin R; Wüthrich RP
    Swiss Med Wkly; 2021 Feb; 151():w20453. PubMed ID: 33638353
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.